Hummingbird uses VISTA buzz to secure $290M pact for phase 2-ready tumor drug
Hummingbird Biosciences could one day feather its nest with up to $290 million if its decision to license a phase 2-ready cancer drug to Percheron Therapeutics pays off.
Hummingbird Biosciences could one day feather its nest with up to $290 million if its decision to license a phase 2-ready cancer drug to Percheron Therapeutics pays off.
